Atherogenic Effects of Anabolic Steroids on Serum Lipid Levels
作者： Gary Glazer
DOI: 10.1001/ARCHINTE.1991.00400100013003
关键词:
摘要: This article reviews the current body of literature linking anabolic steroids to atherogenic alterations in serum lipid levels. Anabolic cause marked high-density lipoprotein level depression (weighted average, 52%) and severe lipoproteinb levels 78%) while raising low-density an average 36%. The mechanism these changes, their time course relation steroid use, dependency on route administration are discussed. Interpretation observed changes light epidemiologic data lipids coronary heart disease risk is used estimate lipid-based increase due use. (Arch Intern Med. 1991;151:1925-1933)
ama-assn.org
sci-hub.se 参考文章(68)
KARL E. FRIEDL, ROBERT E. JONES, CHARLES J. HANNAN, STEPHEN R. PLYMATE, The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance The Journal of Clinical Endocrinology and Metabolism. ,vol. 68, pp. 971- 975 ,(1989) , 10.1210/JCEM-68-5-971
Hugh McA. Taggart, Deborah Applebaum-Bowden, Steven Haffner, G.Russell Warnick, Marian C. Cheung, John J. Albers, Charles H. Chestnut, William R. Hazzard, Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis Metabolism. ,vol. 31, pp. 1147- 1152 ,(1982) , 10.1016/0026-0495(82)90166-4
Robert W. Stout, Overview of the Association Between Insulin and Atherosclerosis Metabolism-clinical and Experimental. ,vol. 34, pp. 7- 12 ,(1985) , 10.1016/S0026-0495(85)80003-2
U. Zuliani, B. Bernardini*, A. Catapano**, M. Campana, G. Cerioli, M. Spattini, Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. International Journal of Sports Medicine. ,vol. 10, pp. 62- 66 ,(1989) , 10.1055/S-2007-1024877
W P Castelli, J T Doyle, T Gordon, C G Hames, M C Hjortland, S B Hulley, A Kagan, W J Zukel, HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. ,vol. 55, pp. 767- 772 ,(1977) , 10.1161/01.CIR.55.5.767
Robert I. Levy, Cholesterol and coronary artery disease what do clinicians do now The American Journal of Medicine. ,vol. 80, pp. 18- 22 ,(1986) , 10.1016/0002-9343(86)90156-7
Deborah Applebaum-Bowden, Steven M. Haffner, William R. Hazzard, The dyslipoproteinemia of anabolic steroid therapy: Increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol Metabolism-clinical and Experimental. ,vol. 36, pp. 949- 952 ,(1987) , 10.1016/0026-0495(87)90130-2
Graham McKillop, David Ballantyne, Lipoprotein analysis in bodybuilders International Journal of Cardiology. ,vol. 17, pp. 281- 286 ,(1987) , 10.1016/0167-5273(87)90077-5
John J. Albers, Hugh McA. Taggart, Deborah Applebaum-Bowden, Steven Haffner, Charles H. Chesnut, William R. Hazzard, Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochimica et Biophysica Acta. ,vol. 795, pp. 293- 296 ,(1984) , 10.1016/0005-2760(84)90078-X
LOWELL E. IRWIN, Adenosquamous carcinoma of the lung and the acquired immunodeficiency syndrome. Annals of Internal Medicine. ,vol. 100, pp. 158- 158 ,(1984) , 10.7326/0003-4819-100-1-158_2